Pfizer’s Ibrance has met with immense success in metastatic breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust, the company reported late Friday.
In a result that could cost Ibrance access to a multibillion-dollar market, a planned futility analysis of the phase 3 Pallas trial determined that adding the drug to standard postsurgery endocrine therapy was unlikely to significantly lengthen patients’ time before invasive disease returned. The trial tested Ibrance in women and men with HR-positive, HER2-negative early breast cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,